[Use of interferon-alpha (IFN-alpha) in the treatment of keratoacanthoma].
OBJECTIVE
Keratoacanthoma are benign epithelial tumors. The aim of this study was to determine the effects of interferon alpha on keratoacanthoma.


METHODS
Six patients presented with histologically proven keratoacanthoma which were large or otherwise difficult to excise. Intra and perilesional interferon-alpha treatment with 3 million IU weekly was started.


RESULTS
In 6-15 weeks all tumors were cured.


CONCLUSIONS
Treatment with intralesional interferon-alpha offers a new possibility in cases of large keratoacanthomas, or those which are not surgically excisable.
Somlai
B
B
Semmelweis Medizinische Universität, Klinik für Haut- und Geschlechtskrankheiten, Budapest, Ungarn.
Holló
P
P
D000368:Aged; D000369:Aged, 80 and over; D005148:Facial Dermatoses / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D015552:Injections, Intralesional; D016898:Interferon-alpha / Q000008:administration & dosage*; D007636:Keratoacanthoma / Q000188:drug therapy*; D007868:Leg Dermatoses / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D007155:Immunologic Factors; D016898:Interferon-alpha